JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug ...

Scynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be the first broad-spectrum antifungal to reach the US market for vaginal yeast infections in ...

SCYNEXIS (SCYX) announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European ...

SCYNEXIS (NASDAQ:SCYX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th.Analysts expect the company to announce earnings of ...

Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter. U.S. stocks traded mixed toward the end of ...

SCYNEXIS ( NASDAQ:SCYX ) Full Year 2024 Results Key Financial Results Net loss: US$21.3m (down by 132% from US$67.0m... JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ...

Scynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be the first broad-spectrum antifungal to reach the US market for vaginal yeast infections in ...

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including ...

The Company anticipates the restart, pending the FDA’s JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...